Provision of a Managed Service Contract for Cardiac Catheterisation Laboratories

ICHT provides acute and specialist healthcare for a population of nearly two million people in North-West London, and more beyond. It has five hospitals, namely Charing Cross, Hammersmith, Queen Charlotte’s & Chelsea, St Mary’s and The Western Eye, as well as a growing number of community services. With its academic partner, Imperial College London, it is one of the UK’s seven academic health science centres, working to ensure the rapid translation of research for better patient care and excellence in education. ICHT is also part of Imperial College Health Partners, the academic health science network for North-West London, spreading innovation and best practice in healthcare more widely across their region.<br/><br/>ICHT is also a partner within the North-West London Integrated Care Board (ICB). Its procurement and commercial activity is supported by the newly formed North-West London Procurement Shared Services, in which ICHT procurement & commercial team is hosted by the Central London Community Hospital. This new team supports all the Trusts and community hospitals within the ICB to drive economies of scale and encourage collaboration to commission services jointly, where possible. <br/><br/>ICHT has a current managed service provision for its Cardiac Catheterisation Laboratories (Cath Labs) which will expire in the medium term and hence ICHT will be undertaking a competitive tender to re-procure this critical service. The cardiac directorate at Hammersmith Hospital has five (5) Cath Labs (3 x coronary / structural and 2 x electro-physiological). A sixth Cath Lab is under construction and will be commissioned by the end of 2023. The service is currently managed by an incumbent supplier who has provided the service since 2013. <br/><br/>The vision of ICHT is to:<br/><br/>

• Partner with a suitably qualified and experienced manufacturer or economic operator for a period of up to 10-15 years for a future-proofed and innovative Cath Labs MSC, which provides the Trust with the functionality to deliver world class cardiology catheterisation service.<br/>
• Include options for other Trusts to join the contract for the Cath Lab services across the North-West London ICB where it is practical to do so.<br/>
• Continue to deliver world class cardiac services for the population of North-West London and surrounding areas. <br/>
• Be a world leader in transforming health through innovation in patient care, education and research<br/>
• Achieve of value for money through its procurement and commercial activities and explore innovation commercial options whilst working in partnership with suppliers<br/>
• Continue to utilise and benefit from latest medical innovations and technologies<br/>
• Create a culture of continuous improvement to increase and sustain the quality of services for our patients, people and stakeholders<br/>
• Maximise the use of the estate and resources to ensure both optimal Cath Labs performance and a high quality of service for the patients. <br/><br/>ICHT undertook an initial market testing exercise in the first quarter of 2022 and now wishes to undertake a more specific market testing exercise in conjunction with its various Trust partners ahead of formally going-to-market for the Cath Lab service. With the formation of the ICB, ICHT wishes to explore the opportunities for collaboration on the Cath Lab service more widely for a fully managed service across all Cath Labs within the North-West London ICB. The intention of this market engagement activity is to explore commercial options, new technological advances, innovation & partnership opportunities openly and honestly whilst managing commercial risks through the Mutual Non-Disclosure Agreement published with this PIN.<br/><br/>ICHT therefore, now wishes to engage with potential suppliers and economic operators with the capacity, capability and infrastructure to provide a fully managed service for the Cath Labs in order to inform its future requirements, including but not limited to, technical and clinical specifications, commercial & financing models, quality & safety requirements, regulatory approvals, technological capability and system inter-operability, supply chain processes, the implementation plan and associated processes. Furthermore, ICHT wishes to engage in any other current and future products and business activities that the Supplier may wish to collaborate on to facilitate future planning and partnership working. Additional information: Suppliers and economic operators shall be invited to two separate online meetings between August 2023 to October 2023 with the relevant Trust stakeholders. Suppliers and economic operators wishing to participate are invited to sign the NDA and return no later than 12:00 pm on 3rd August 2023 via the e-sourcing portal atamis1928.lightning.force.com/lightning/page/home ↗ and confirm the preferred time slot for the Commercial Engagement Meeting (see below for available time slots). <br/><br/><br/>The plan is to hold two separate engagement meetings focussing on commercial and clinical aspects respectively. At the first engagement meeting, suppliers will be required to present the following information and the slides will need to be submitted through the Atamis portal at least 2 days in advance of the confirmed meeting date: <br/><br/>1) Commercial Engagement Meeting (to be held during August) <br/><br/>An editable power point presentation of no more than 8 - 10 slides to include the following:<br/><br/>a. Company financial information and global client credentials list (1 slide)<br/><br/>b. Market dynamics and competitive landscape, industry trends, supply chain, key risks, challenges and future commercial outlook (2 slides)<br/><br/>c. Commercial model, financing, pricing options alternatives (2- 3 slides)<br/><br/>d. Case studies to include two examples as follows where the supplier or the economic operator has recent hands-on experience of managing a Cath Labs programme…